Pharma channel feed

J&J pre­vails in schiz­o­phre­nia drug patent spat against Te­va

11 hours ago
Law

CoRe­gen clos­es $93M fi­nanc­ing round to en­ter the clin­ic and ex­pand its lead­er­ship team

12 hours ago
Financing
Manufacturing

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

15 hours ago

Trump’s CDC nom­i­nee Monarez ad­vances to full Sen­ate

16 hours ago

Up­dat­ed: Mer­ck drops $10B for res­pi­ra­to­ry drug­mak­er Verona Phar­ma in its first ac­qui­si­tion of 2025

18 hours ago
Deals

FDA ap­proves new dos­ing of Lil­ly’s Alzheimer’s drug to low­er brain swelling risks

19 hours ago

Trump hints at tar­iff grace pe­ri­od for phar­ma com­pa­nies to bring man­u­fac­tur­ing to US

Yesterday
Manufacturing

Ot­su­ka’s Tai­ho re­ports Phase 3 fail for Duchenne mus­cu­lar dy­s­tro­phy drug

Yesterday

In first half of 2025, nov­el drug ap­provals are in line with pre­vi­ous years

Yesterday
FDA+

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

Yesterday
People

No­var­tis maps launch of malar­ia drug for new­borns af­ter Swiss ap­proval

2 days ago

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

2 days ago
R&D
FDA+

Trump's tax cut law ex­pands or­phan drug ex­clu­sions, could up­end 340B pro­gram

2 days ago
Law

The Supreme Court passed on a state PBM case. Lawyers say a broad­er le­gal fight is brew­ing

2 days ago
Law

KalVista CEO says FDA re­view pro­ceed­ed nor­mal­ly, was un­aware of Makary's re­jec­tion ask

2 days ago
People
FDA+

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

2 days ago

HHS ac­tions to re­move web con­tent were ar­bi­trary, 'poor­ly thought-through,' judge rules

6 days ago
Law

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

6 days ago
R&D

The Trump ad­min­is­tra­tion is pro­mot­ing wear­able health de­vices — with or with­out ev­i­dence

6 days ago
Health Tech

Dizal’s lung can­cer pill ap­proval sets up com­pe­ti­tion with J&J

6 days ago
FDA+

FDA re­view­ers ad­vised broad la­bel for Mod­er­na’s next-gen Covid vac­cine. Prasad over­ruled them

Last week
FDA+

Ab­b­Vie los­es bid to block Ten­nessee's 340B con­tract phar­ma­cy law

Last week
Law

CDC ex­pands RSV vac­cine rec­om­men­da­tions, sid­ing with pre­vi­ous pan­el of agency ad­vi­sors

Last week
FDA+

Af­ter de­lay, Re­gen­eron wins US ap­proval of bis­pe­cif­ic in mul­ti­ple myelo­ma

Last week
FDA+
1234 Next page Last page
A service from the Financial Times